Connecting Innovation to Purpose

A diversified pipeline with differentiated clinical risk profiles CRB-701 Next-generation Nectin-4 targeting ADC CRB-601 Anti-av38 mAb (TGF6-targeting) CRB-913 CB1R inverse agonist Nectin-4 positive solid tumors Next-Generation Nectin-4 targeting ADC Dose Escalation Cohorts 1-6 completed Cohort 7 added and recruiting CSPC (China) Corbus (US + Europe) avß8 enriched solid tumors Dose Escalation Obesity and related conditions Anti-Integrin mAb Highly peripherally-restricted CB1R inverse agonist Dose Confirmation / Expansion Cohort 6 expanding Dose Confirmation / Expansion IND Cleared in January 2024 IND Expected in Q4 2024

View entire presentation